Mylan Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs

MYL 15.86

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Lawrence who wrote (314)	5/20/1998 8:21:00 AM
From: B. W. Lewis	Read Replies (1) of 384

David, Don't get to excited about the news out of Somerset. Eldepryl has a significant side effect profile that other products currently on the market for depression, and a couple awaiting approval, are lacking. Furthermore, Somerset appears to be sometime away from filing an NDA which means that they are a minimum of two years away from launching the product. The better news is that several Maxzide-25 generic products are currently on the market and in all likelihood the Barr product will not significantly bite into the Maxzide market share but rather intensify the competition in the generic market. BWL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next